Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it

Bristol Myers Squibb focuses on specialized medicines in oncology and immunology, and shares sport a

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

A bipartisan group of United States lawmakers has opened national security investigations into wheth

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology c

In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.56, marking a +1.81% move fr

At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

Bristol Myers Squibb maintains a robust biopharmaceutical portfolio focused on high-stakes oncology

The Nasdaq 100 has tripled since 2020, but 10 mega-caps still trade below pre-Covid levels. Who'

Elicio shares complete response data for ELI-002 7P in KRAS pancreatic cancer and plans combination

Bristol Myers Squibb Canada (BMS) is pleased to announce an update to the Canadian product monograph

Takeda's psoriasis drug zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a Phase 3

Multiple myeloma is a complex and incurable blood cancer, characterized by a relentless cycle of rel

Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on d

Interim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented a

Replimune Group (REPL) shares gain on key RP2 & RP1 oncology data presentations at ASCO. Read th

Camzyos has the potential to be the first pharmacological therapy for the treatment of oHCM in adole

This approval marks a significant milestone, establishing the Opdivo plus AVD combination as the fir

In turbulent markets, investors turn to dividend-yielding stocks. Here are analyst ratings for high-

Bristol Myers Squibb (NYSE:BMY) today announced positive late-breaking results from the Phase 3 SUCC

Bristol Myers deploys Claude enterprise AI to 30,000 workers as Anthropic stacks enterprise wins aga

Bristol Myers Squibb expands AI efforts through Anthropic and Tempus partnerships as shares edge hig

The collaboration brings together BMS' deep scientific expertise and Anthropic's frontier AI

In times of market turbulence, investors turn to dividend-yielding stocks. Benzinga provides real-ti

Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges t

The US Supreme Court turned away appeals from six pharmaceutical companies seeking to topple the Med

Tempus AI And Bristol Myers Squibb Expand AI-Driven Trial Design Efforts Across Oncology And Alzheim

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision m

Bristol Myers Squibb unveiled a multibillion-dollar partnership with Hengrui Pharma spanning 13 drug

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and h

In the pivotal Phase 3 POETYK PsA clinical trials, Sotyktu demonstrated superiority compared with pl

Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook

Robert F. Kennedy Jr. unveiled a federal initiative to curb the overuse of psychiatric medications,

Bristol-Myers Squibb beats Q1 2026 estimates as growth drugs lift revenue, while the legacy portfoli

Investors turn to dividend-yielding stocks during market turbulence. Benzinga's database offers

Bristol-Myers Squibb (NYSE:BMY) affirms FY2026 Adj EPS guidance from $6.05-$6.35 to $6.05-$6.35 vs $

Bristol-Myers Squibb (NYSE:BMY) reported quarterly earnings of $1.58 per share which beat the analys

Expands Options for Cash-Paying Patients to Access the Nation's #1 Prescribed Oral Blood Thinner

Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its

Beeline Medicines Corporation ("Beeline Medicines" or "the Company"), a clinical-sta

FDA says Replimmune melanoma therapy lacks sufficient efficacy evidence, citing trial flaws and limi

Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9%

B of A Securities analyst Tim Anderson maintains Bristol-Myers Squibb (NYSE:BMY) with a Buy and l

Oxford BioTherapeutics ("OBT"), is a clinical stage oncology company focused on the discover